Bilcare Ltd
About
Bilcare is a trailblazer in the Indian pharmaceutical and healthcare sectors. It offers specialty polymer films and aluminium foils for the packaging of pharmaceutical products that can come in solid dosage forms. Its packaging innovations include blister foils and films, lidding foils, CR foils, and laminates. Its R&D department is primarily engaged in the study of formulation stability, packaging trials and audits, and designing and developing blister foils.With an annual manufacturing capacity of 5000 tonnes and operating procedures within the US Food and Drug Administration guidelines, Bilcare exports its products to more than 100 countries globally. Some of its notable clients include Cipla, Sun Pharma, Serum Institute of India, Novartis, and Procter & Gamble.
Featured In Fortune India Ranking
Financial Data 2024
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 789 -39.1% | 1295 43.8% | 900 32.4% | 680 -63.8% | 1878 -38.4% | 3051 -2.9% | 3141 16.6% | 2693 -10.0% | 2992 11.4% | 2687 -13.8% | 3116 -13.1% | 3587 -2.2% | 3667 57.0% | 2336 119.1% | 1066 22.0% | 874 - |
| Net Operating Income (INR Cr) | 747 -23.88% | 982 16.21% | 845 35.65% | 623 -65.92% | 1827 -39.04% | 2997 7.87% | 2778 5.53% | 2633 1.15% | 2603 -3.32% | 2692 -12.07% | 3062 -13.67% | 3547 -2.61% | 3642 59.27% | 2287 118.22% | 1048 22.41% | 856 31.56% |
| Profit (INR Cr) | -33 - | 15 - | -13 - | -21 - | -104 - | -455 - | -201 - | -85 - | -85 - | -216 - | -113 - | 40 -71.0% | 137 -7.4% | 148 26.1% | 117 41.0% | 83 - |
| Assets (INR Cr) | 1406 4.4% | 1346 53.5% | 877 -2.3% | 898 -5.3% | 948 -62.4% | 2524 -8.2% | 2748 -4.2% | 2870 -5.5% | 3035 -14.6% | 3554 -3.5% | 3684 2.0% | 3613 22.1% | 2959 22.8% | 2409 63.7% | 1472 1.8% | 1446 - |
| Net Worth (INR Cr) | 498 141.2% | 206 174.6% | 75 -12.9% | 86 -20.3% | 108 255.1% | -70 -117.5% | 400 -34.8% | 614 -13.9% | 713 -35.0% | 1096 -17.2% | 1324 -0.1% | 1325 -0.6% | 1334 25.3% | 1065 22.0% | 873 76.0% | 496 26.2% |
| Employee Cost (INR Cr) | 72 0.9% | 71 20.2% | 59 7.2% | 55 -85.1% | 371 -39.9% | 617 10.5% | 559 6.5% | 524 2.7% | 510 -6.8% | 548 -2.7% | 563 6.0% | 531 -1.7% | 540 63.3% | 331 243.2% | 96 11.6% | 86 - |
| Interest Cost (INR Cr) | 82 | 60 | 69 | 76 | 174 | 283 | 249 | 176 | 151 | 236 | 217 | 167 | 165 | 99 | 44 | 39 |
| Cash & Bank Balance (INR Cr) | 36 | 31 | 40 | 57 | 64 | 91 | 100 | 124 | 110 | 156 | 106 | 94 | 173 | 178 | 152 | 105 |
| Total Debt (INR Cr) | 756 | 639 | 690 | 677 | 707 | 2270 | 2089 | 2014 | 2122 | 2311 | 2146 | 2104 | 1371 | 1190 | 599 | 950 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | - | 1.2% | - | - | - | - | - | - | - | - | - | 1.1% | 3.7% | 6.3% | 11.0% | 9.5% |
| Profit As % Of Assets | - | 1.1% | - | - | - | - | - | - | - | - | - | 1.1% | 4.6% | 6.1% | 7.9% | 5.7% |
| Profit As % Of Networth | - | 7.3% | - | - | - | - | - | - | - | - | - | 3.0% | 10.2% | 13.9% | 13.4% | 16.7% |
| Interest Cost to EBITDA % | 251.6% | - | 121.3% | 163.1% | 395.8% | 167.9% | 158.3% | 93.6% | - | 158.0% | 89.4% | 46.4% | 34.5% | 28.7% | 18.1% | 21.1% |
| Debt to Equity Ratio | 1.52 | 3.09 | 9.18 | 7.85 | 6.53 | - | 5.22 | 3.28 | 2.98 | 2.11 | 1.62 | 1.59 | 1.03 | 1.12 | 0.69 | 1.92 |
| RONW | - | -8.3% | - | - | - | - | - | - | - | - | - | 4.2% | 11.2% | 15.1% | 17.1% | 18.7% |
| ROCE | 0.0% | 2.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.1% | 3.0% | 7.5% | 13.2% | 15.5% | 14.4% | 12.5% |